The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Approaches to newly diagnosed myeloma and the rapidly evolving landscape
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, provides a comprehensive summary of his talk on approaches to newly diagnosed multiple myeloma (MM) and the rapidly evolving treatment landscape in this setting. He highlights the importance of tailored treatment strategies due to the genetic instability of the disease and emphasizes that one size does not fit all in the context of myeloma treatment. Dr Richardson also discusses the success of quadruplet regimens, which have revolutionized the frontline treatment landscape, and comments on the evolving role of transplantation. Finally, Dr Richardson presents some interesting findings from the DETERMINATION study (NCT01208662), which elucidated the possible impact of the Duffy null phenotype on the pathobiology and treatment outcomes in myeloma. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Celgene/Bristol Myers Squibb, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron, Sanofi: Consultancy; Oncopeptides: Research Funding.
